

Is Quality of Life Data Predictive of the Survival in Cancer Patients? A Rapid and Systematic Review of the Literature

Montazeri A¹

Abstract

Objective: To review literature on relationship between quality of life data and the length of survival in cancer patients.

Methods: A literature search was carried out using MEDLINE to assess existing knowledge on relationship between quality of life data as a prognostic factor and survival in cancer patients. The intention was to review all full publications in English language biomedical journals. The search strategy included the combination of keywords 'cancer', 'prognostic', 'predictor', 'predictive', 'quality of life' and 'survival' in titles of publications. The literature was also examined to ensure that the study used multivariate analyses. Pure psychological studies were excluded. The initial search was carried out twice in December 2008 and twice for a final check in early and late January 2009. A manual search also was performed for including possible additional papers.

Results: In all 146 citations were identified and reviewed. Of these, 88 citations on relationship between quality of life and survival were found relevant and examined in this rapid and systematic review of the literature. The findings are summarized under different headings including studies on heterogeneous sample of cancer patients, lung cancer, breast cancer, gastro-oesophageal cancers, colorectal cancer and other cancers. Except a few exceptions most studies found that quality of life data or some aspects of quality of life measures were significant independent predictors of survival duration. Global quality of life, functioning domains and symptom scores such as appetite loss, fatigue and pain individually or in combined were the most important factors that predicted the length of survival in cancer patients after adjusting for one or more demographic and known clinical prognostic factors.

Conclusion: Studies reported in this review provide evidence for a positive relationship between quality of life data or some aspects of quality of life measures and the length of survival in cancer patients. Pre-treatment quality of life data are appeared to be most reliable information that could help clinicians to establish prognostic criteria for treatment of their cancer patients. Indeed, conducting studies using valid instruments, applying sound methodological approaches and adequate but not sophisticated multivariate statistical analyses adjusted for demographic characteristics and known clinical prognostic factors are recommended in order to yield more specific quality of life related prognostic variables for specific cancers.

Keywords: quality of life, prognostic factor, predicting factor, survival, cancer, patient-reported outcomes

1. Professor in Public Health and Epidemiology, Iranian Institute for Health Sciences Research, ACECR, Tehran, Iran

Corresponding Author:

A. Montazeri

Email: montazeri@acecr.ac.ir

IJCP 2009; 1: 1-14

Introduction

Health-related quality of life is now considered an important endpoint in studies of outcomes in oncology. Studies of quality of life can indicate the directions needed for more efficient treatment of cancer patients. In addition it has been shown that

assessing quality of life in cancer patients could contribute to improved treatment and could even be as prognostic as medical factors [1-6].

The aim of this review was to examine literature published since the topic first appeared in English language biomedical journals. It was hoped that this review may contribute to existing knowledge, help

both researchers and clinicians to have a better profile on the topic, and consequently aid in improving quality of life in cancer patients.

Methods

A literature search was carried out using MEDLINE to assess existing knowledge on relationship between quality of life data as a prognostic factor and survival in cancer patients. The intention was to review all full publications that have been appeared in English language biomedical journals between 1982 and 2008. The year 1982 was chosen because the first study on the topic was published then. The search strategy included the combination of keywords 'cancer', 'prognostic', 'predictor', 'predictive', 'quality of life' and 'survival' in titles of publications. The literature was also examined to ensure that the study used multivariate analyses. Pure psychological studies were excluded. It was thought that this might help to focus the investigation. It provided the initial database for the review. The initial search was carried out twice in December 2008 and twice for a final check in early and late January 2009. A manual search also was performed for including possible additional papers.

Results

Statistics

A total of 146 citations were identified and after exclusion of duplicates, the abstracts of 135 citations were reviewed. Of these, 88 citations on relationship between quality of life and survival were identified and examined in this rapid and systematic review of the literature. Here, the major findings are summarized and presented under the following headings.

Early studies

It was in 1980s that a few papers reported on positive relationships between some psychosocial and quality of life parameters and the length of survival in cancer patients. The first paper on relationship between quality of life data and survival in cancer patients was published in 1982. In this paper existing records of 651 patients with bronchogenic carcinoma were assessed in order to determine the relationship between survival and four 'non-anatomic' prognostic factors including symptomatic history, performance status, weight loss and age. Adjusting for stage, histologic factors and treatment, the analysis showed that weight loss and performance status were significantly associated with survival [7]. In 1985 Cassileth et al. reported that studying 359 cancer patients they did not find any association between

social and psychological factors and the length of survival or the time to relapse. They did not collect data on health related quality of life but they concluded that although these factors may contribute to the initiation of morbidity, the biology of the disease appears to predominate and to override the potential influence of life-style and psychosocial variables once the disease process is established [8]. The third paper on the topic was appeared in 1987. This paper compared quality of life during chemotherapy for advanced breast cancer receiving intermittent and continuous treatment strategies. The study findings indicated that changes in the quality of life scores, as measured by a series of Linear Analog Self Assessment (LASA) scales for physical well-being, mood, pain, and appetite (as quality of life index), were independent prognostic factors in proportional hazards models of subsequent survival [9]. Kaasa et al. also published a paper on the topic in 1989. They in their study of inoperable non-small-cell lung cancer showed that general symptoms and psychological well-being were the best predictive value for survival duration [10].

Heterogeneous sample of cancer patients

There were studies that included a heterogeneous sample of cancer populations [11-16]. Global quality of life, physical, social, emotional and cognitive functioning were found to be independent prognostic factors for survival. The results are shown in Table 1.

Lung cancer

There were relatively considerable studies that examined the relationship between quality of life data and survival in lung cancer patients [7,10,17-38]. The studies included a sample of either lung cancer patients (both small-cell and non-small-cell) or mostly advanced non-small-cell lung cancer patients. Except one study that reported overall quality of life score was not predictor of survival [22], in most instances baseline overall or global quality of life scores were found to be independent prognostic factor of survival duration. In addition, in many studies pain, and appetite loss were found to be independent determinants of overall survival. Table 2 summarizes the results.

Breast cancer

Studies that examined the relationship between quality of life data and survival in breast cancer patients are presented in Table 3 [9,39-56]. Studies have shown that baseline quality of life predicts

Table 1: Studies on relationship between quality of life data and survival in heterogeneous sample of cancer patients

Author(s)	Year	Cancer	HRQOL measure(s)	Results*
Degner and Sloan [11]	1995	Ambulatory heterogeneous sample of cancer patients	SDS	The single measure of symptom distress was a significant predictor of survival.
Ringdal et al. [12]	1996	Heterogeneous sample of cancer patients	Psychosocial variables	Physical functioning was prognostic factor of survival but psychosocial covariates were not.
Tamburini et al. [13]	1996	Terminal cancer patients	TIQ	Confusion, cognitive status and global health status were independent prognostic of survival.
Coates et al. [14]	1997	Advanced malignancies	EORTC QLQ-C30	Global QOL and social functioning were significantly predictive of survival.
Dancey et al. [15]	1997	Heterogeneous population of cancer patients	EORTC QLQ-C30	Global QOL and emotional functioning were significantly associated with survival.
Chang et al. [16]	1998	Heterogeneous sample of cancers patients (colon, breast, ovary or prostate)	MSAS	Physical symptom subscale score significantly predicted survival.

Abbreviations: EORTC QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire; MSAS: Memorial Symptom Assessment Scale; QOL: quality of life; SDS: Symptom Distress Scale; TIQ: Therapy Impact Questionnaire.

* All results obtained from multivariate analyses after controlling for one or more demographic and known biomedical prognostic factors.

survival in advanced breast cancer but not in early stage of disease [44]. Two recently published papers also confirmed that baseline quality of life was not a prognostic factor in non-metastatic breast cancer patients. One of these two studies, using Cox survival analysis, indicated that neither health-related quality of life nor psychological status at diagnosis or 1 year later was associated with medical outcome in women with early-stage breast cancer [52]. The other study, on a sample of 448 locally advanced breast cancer patients, reported that baseline health-related quality of life parameters had no prognostic value in a non-metastatic breast cancer population [50]. However, A study using the Daily Diary Card to measure quality of life in advanced breast cancer showed that the instrument offered accurate prognostic data regarding subsequent response to treatment and survival duration [40]. Similarly, Seidman et al. [41] evaluated quality of life in two phase II clinical trials of metastatic breast cancer and found that baseline scores of two validated quality of life instruments independently predicted the overall survival. In addition, studies have demonstrated that some aspects of quality of life data including physical health [39], pain [45,48], and loss of appetite [51] are significant prognostic factors for survival in women with advanced breast cancer. In addition, one study demonstrated that baseline physical aspects of quality of life and its changes were related to survival, but psychological and social aspects were not [46].

Gastro-oesophageal cancers

The findings are summarized Table 4 [57-63]. Studies have shown that physical functioning was an important prognostic factors of survival in this group of cancer patients. Symptoms such as fatigue, reflux and appetite loss also were found to be independent prognostic factors of survival duration in patients with either gastric or oesophageal cancers.

Colorectal cancer

Social functioning as measured by the EORTC QLQ-C30 or health and physical subscales as measured by the Ferrans and Powers Quality of Life Index were shown to be prognostic factors of survival in colorectal cancer patients. The results are shown in Table 5 [19,64-68].

Other Cancers

Other studies of relationship between quality of life data and survival reported findings on different cancer populations including brain, ovarian, liver and bladder cancers. The findings of such studies are presented in Table 6. Except two studies in live and ovarian cancer patients [Fielding and Wong, Gupta et al], other studies found a significant relationship between quality of life scores and survival duration in these patients. The results are summarized in Table 6 [8, 37, 69-94].

Table 2: Studies on relationship between quality of life data and survival in patients with lung cancer

Author(s)	Year	Cancer	HRQOL measure(s)	Results*
Pater and Loeb [7]	1982	Bronchogenic carcinoma	Symptomatic history, performance status, weight loss and age	Weight loss and performance status were significantly affected survival.
Kaasa et al. [10]	1989	Inoperable non-small-cell	Psychological well-being + disease-related symptoms + personal functioning + everyday activity	General symptoms and psychological well-being were the best predictive value for survival.
Ganz et al. [17]	1991	Advanced metastatic lung cancer	FLI-C	A statistically significant relationship was observed between initial patient-rated QOL and subsequent survival.
Ruckdeschel et al. [18]	1994	Lung cancer	FLI-C	Total FLI-C score was significant predictor of survival.
Loprinzi et al. [19]	1994	Advanced colorectal or lung	A designed questionnaire	Patients' assessment of their own performance status and nutritional factors such as appetite, caloric intake, or overall food intake were prognostic of survival.
Buccheri et al. [20]	1995	Lung	TIQ	The self-estimated difficulty at work and doing housework were significant independent prognostic determinants of survival.
Buccheri et al. [21]	1998	Lung	SDS	Depression was associated with survival.
Herndon et al. [22]	1999	Advanced non-small-cell	EORTC QLQ-C30 + Duke-UNC Social Support Scale	Pain was a significant predictor of survival but overall QOL was not.
Langendijk et al. [23]	2000	Inoperable non-small-cell lung	EORTC QLQ-C30	Global QOL was a strong prognostic factor of survival.
Montazeri et al. [24]	2001	Lung (small and non-small-cell)	NHP + EORTC QLQ-C30 + QLQ-LC13	Baseline global QOL was most significant predictor of the length of survival.
Auchter et al. [25]	2001	Non-small cell	FACT-L (TOI)	The change in TOI score was not associated with survival. A trend was noted for shorter survival with the largest negative change in TOI score.
Moinpour et al. [26]	2002	Advanced non-small-cell	FACT-L	Total FACT-L score was predictor of survival.
Nakahara et al. [27]	2002	Advanced lung cancer	Tokyo University Egogram	Mental state was prognostic of survival.
Naughton et al. [28]	2002	Small-cell	EORTC QLQ-C30 + CES-D + MOS Social Support Questionnaire + a sleep quality scale	Higher depressive symptoms were borderline significant in predicting decreased survival.
Eton et al. [29]	2003	Advanced non-small-cell	FACT-L + TOI	Baseline physical well-being and TOI scores predicted either survival duration or disease progression respectively.
Dharma-Wardene et al. [30]	2004	Advanced lung cancer	FACT-G	Baseline FACT-G total score was significantly associated with survival.
Nowak et al. [31]	2004	Pleural mesothelioma	EORTC QLQ-C30 + QLQ-LC13	Functional domains and symptom scales (fatigue, pain) demonstrated predictive validity for survival.
Maione et al. [32]	2005	Advanced non-small-cell lung cancer	ADL + IADL + EORTC QOL-C30 (global QOL)	Baseline global QOL and IADL were significant prognostic factors for overall survival.

Table 2 (continued): Studies on relationship between quality of life data and survival in patients with lung cancer

Author(s)	Year	Cancer	HRQOL measure(s)	Results*
Brown et al. [33]	2005	Non-small-cell lung cancer	EORTC QLQ-C30 + QLQ-LC17 + DDC	Global QOL, role functioning, fatigue, appetite loss and constipation were prognostic indicators of survival.
Efficace et al. [34]	2006	Advanced non-small-cell lung cancer	EORTC QLQ-C30 + QLQ-LC13	Pain, and dysphagia were significant prognostic factors for survival.
Sundstrom et al. [35]	2006	Stag III non-small-cell lung cancer	EORTC QLQ-C30	Appetite loss was the most significant prognostic factor of survival.
Bottomley et al. [36]	2007	Malignant pleural mesothelioma	EORTC QLQ-C30 + QLQ-LC13	Pain, and appetite loss were independent prognostic indicators of survival.
Fielding and Wong [37]	2007	Liver and lung cancer	FACT-G	Global QOL scores did not predict survival in liver cancer. Physical well-being predicted survival in lung cancer.
Jacot et al. [38]	2008	Non-small-cell lung cancer	LCSS	Global symptoms score was independent determinants of overall survival.

Abbreviations: CES-D: Centre for Epidemiologic Studies-Depression Scale; DDC: Daily Diary Card; EORTC QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire; FACT-G: Functional Assessment of Cancer Therapy-General module; FACT-L: Functional Assessment of Cancer Therapy-Lung module; FLI-C: Functional Living Index-Cancer; IADL: Instrumental Activities of Daily Living; LCSS: Lung Cancer Symptoms Scale; MOS: Medical Outcomes Study; ADL: Activities of Daily Living; NHP: Nottingham Health Profile; QLQ-LC13 (or QLQ LC17): EORTC Lung Cancer specific Quality of Life Questionnaire (previously containing 17 items); QOL: quality of life; SDS: Self-rating Depression Scale; TIQ: Therapy Impact Questionnaire; TOI: Trial Outcome Index.

* All results obtained from multivariate analyses after controlling for one or more demographic and known biomedical prognostic factors.

Table 3: Studies on relationship between quality of life data and survival in patients with breast cancer

Author(s)	Year	Cancer	HRQOL measure(s)*	Results**
Coates et al. [9]	1987	Advanced breast cancer	LASA scores for physical well-being + mood, pain, and appetite (as QOL index)	Changes in QOL scores were independent prognostic of survival.
Coates et al. [39]	1992	Advanced breast cancer	LASA scores for physical well-being + mood, nausea, vomiting, and appetite (as QOL index)	Both QOL index and physical well-being were independent prognostic factors of survival.
Fraser et al. [40]	1993	Advanced breast cancer	DDC + LASA + NHP	The DDC provided accurate prognostic data regarding subsequent response and survival.
Seidman et al. [41]	1995	Advanced breast cancer	MSAS + MSAS-GDI + FLI-C + RMHI + BPI + MPAC	Baseline global QOL and distress index scores independently predicted the overall survival.
Tross et al. [42]	1996	Early stage breast cancer	SCL-90-R	No significant predictive effect of the level of depression on length of disease-free and overall survival observed.
Watson et al. [43]	1999	Early stage breast cancer	MAC + CECS + HADS	Depression score of the HADS and helplessness and hopelessness category of the MAC had determinant effect on survival.
Coats et al. [44]	2000	Metastatic and early stage breast cancer	Physical well-being + mood, appetite, and coping (as QOL index)	Disease-free survival was not significantly predicted by QOL scores at baseline or by changes in QOL scores. After relapse QOL scores were predictive for subsequent survival.
Kramer et al. [45]	2000	Advanced breast cancer	EORTC QLQ-C30	Pain was prognostic for survival. However, fatigue and emotional functioning were significant in backward selection model.

Table 3 (continued): Studies on relationship between quality of life data and survival in patients with breast cancer

Author(s)	Year	Cancer	HRQOL measure(s)*	Results**
Shimozuma et al. [46]	2000	Advanced or end stage breast cancer	QOL-ACD	Physical aspects of QOL were significantly related to survival. The change in scores of both overall QOL and the physical aspects of QOL were also significant predictors of survival.
Butow et al. [47]	2000	Metastatic breast cancer	Cognitive appraisal of threat + coping + psychological adjustment + perceived aim of treatment + social support + QOL	Minimization was associated with longer survival while a better appetite predicted shorter duration of survival.
Luoma et al. [48]	2003	Advanced breast cancer	EORTC QLQ-C30	Baseline severe pain was predictive for a shorter overall survival. QOL scores had no great importance in predicting primary clinical endpoints such as time to progression or overall survival.
Winer et al. [49]	2004	Metastatic breast cancer	FLI-C + SDS	Global QOL and symptom distress scores were prognostic for survival.
Efficace et al. [50]	2004	Nonmetastatic breast cancer	EORTC QLQ-C30	Baseline QOL had no prognostic value.
Efficace et al. [51]	2004	Metastatic breast cancer	EORTC QLQ-C30 + QLQ-BR23	Loss of appetite was a significant prognostic factor for survival.
Goodwin et al. [52]	2004	Early stage breast cancer	EORTC QLQ-C30 + PMS + PAIS + IES + MACS + ACS + CECS	QOL and psychological status at diagnosis and 1 year later were not associated with medical outcome.
Watson 2005 et al. [53]	2005	Early stage breast cancer	MAC + HADS	Helplessness/hopelessness was a significant predictor of disease-free survival but depression was not.
Lehto et al. [54]	2006	Localized breast cancer	Coping + emotional expression + perceived support + life stresses + QOL	Longer survival was predicted by a minimizing-related coping while shorter survival was predicted by anti-emotionality, escape coping, and high level of perceived support.
Gupta et al. [55]	2007	Breast carcinoma	Ferrans and Powers QLI	Baseline patient satisfaction with health and physical functioning and overall HRQOL were significant prognostic of survival.
Groenvold et al. [56]	2007	Breast cancer	EORTC QLQ-C30 + HADS	Emotional functioning and fatigue were independent predictors of survival.

Abbreviations: ACS: Adjustment to Cancer Scale; BPI: Brief Pain Inventory; CECS: Courtauld Emotional Control Scale; DDC: Daily Dairy Card; EORTC QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire; FLIC: Functional Living Index-Cancer; HADS: Hospital Anxiety and Depression Scale; IES: Impact of Events Scale; LASA: Linear Analog Self Assessment; MAC: Mental Adjustment to Cancer Scale; MPAC: Memorial Pain Assessment Card; MSAS: Memorial Symptom Assessment Scale; MSAS-GDI: Memorial Symptom Assessment Scale-Global Distress Index; NHP: Nottingham Health Profile; PAIS: Psychological Adjustment to Illness Scale; PMS: Profile of Mood States; QLI: Quality of Life Index; QOL: quality of life; QOL-ACD: Quality of Life Questionnaire for Cancer Patients Treated with Anticancer Drugs; RMHL: Rand Mental Health Inventory; SCL-90-R: Symptom Check List-90 items-Revised; SDS: Symptom Distress Scale.

* All results obtained from multivariate analyses after controlling for one or more demographic and known biomedical prognostic factors.

Table 4: Studies on relationship between quality of life data and survival in patients with gastro-oesophageal cancers

Author(s)	Year	Cancer	HRQOL measure(s)	Results*
Blazeby et al. [57]	2000	Oesophageal	EORTC QLQ-C30 + Dysphagia scale of QLQ-OES24	Physical functioning at baseline was significantly associated with survival.
Blazeby et al. [58]	2001	Oesophageal	EORTC QLQ-C30 + Dysphagia scale of QLQ-OES24	Physical functioning at baseline was significantly associated with survival. After treatment, improved emotional functioning was significantly related to longer survival.
Fang et al. [59]	2004	Oesophageal squamous cell	EORTC QLQ-C30	Pretreatment physical functioning was the most significant survival predictor while QOL scores during treatment were not. After treatment dysphagia was the most significant predictor.
Chau et al. [60]	2004	Locally advanced or metastatic esophago-gastric	EORTC QLQ-C30	Pretreatment physical and role functioning and global QOL predicted survival.
Park et al. [61]	2008	Advanced gastric	EORTC QLQ-C30	Social functioning was significant prognostic factor for survival.
Bergquist et al. [62]	2008	Advanced oesophageal	EORTC QLQ-C30 + QLQ-OES18	Physical functioning, fatigue and reflux were significant prognostic of survival.
McKernan et al. [63]	2008	Gastric or oesophageal	EORTC QLQ-C30	Appetite loss was significantly independent predictor of survival.

Abbreviations: EORTC QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire; QLQ-OES18 (previously QLQ-OES24): EORTC Oesophageal Cancer specific Quality of Life Questionnaire; QOL: quality of life.

* All results obtained from multivariate analyses after controlling for one or more demographic and known biomedical prognostic factors.

Table 5: Studies on relationship between quality of life data and survival in patients with colorectal cancer

Author(s)	Year	Cancer	HRQOL measure(s)	Results*
Loprinzi et al. [19]	1994	Advanced colorectal or lung	A designed questionnaire	Patients' assessment of their own performance status and nutritional factors such as appetite, caloric intake, or overall food intake were prognostic of survival.
Earlam et al. [64]	1996	Colorectal with liver metastases	RSCL + HADS + SIP	Diarrhea, eating, restlessness, and ability to work and sleep were predictors of survival.
Maisey et al. [65]	2002	Locally advanced and metastatic colorectal	EORTC QLQ-C30	Baseline physical, role, social, emotional functioning, global QOL and pain, nausea, dyspnea, and sleep difficulties were strong independent predictors of survival.
Lis et al. [66]	2006	Colorectal	Ferrans and Powers QLI	Health and physical subscale was predictive of survival.
Efficace et al. [67]	2006	Metastatic colorectal	EORTC QLQ-C30	Social functioning was a prognostic measure of survival beyond a number of previously known biomedical parameters.
Efficace et al. [68]	2008	Metastatic colorectal	EORTC QLQ-C30	Social functioning was prognostic factor for survival.

Abbreviations: EORTC QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire; HADS: Hospital and Anxiety Depression Scale; QLI: Quality of Life Index; QOL: quality of life; RSCL: Rotterdam Symptom Checklist; SIP: Sickness Impact Profile.

* All results obtained from multivariate analyses after controlling for one or more demographic and known biomedical prognostic factors.

Table 6: Studies on relationship between quality of life data and survival in patients with different cancers

Author(s)	Year	Cancer	HRQOL measure(s)	Results*
Cassileth et al. [8,69]	1985 and 1988	Unresectable cancers + early stage melanoma or breast	Social and psychological factors	Social and psychological factors individually or in combined did not influence the length of survival.
Coates et al. [70]	1993	Metastatic melanoma	LASA scales + Spitzer QLI	QLI and LASA scores for mood, appetite, and overall QOL were significant predictors of survival.
Tannock et al. [71]	1996	Symptomatic hormone-resistant prostate	EORTC QLQ-C30 + QLQ-PR25 + PROSQOLI	Appetite loss, pain, and physical functioning were associated with survival.
Wisloff and Hjorth [72]	1997	Multiple myeloma	EORTC QLQ-C30	Physical functioning was independent prognostic factor of survival.
De Bore [73]	1998	Head and neck	Self-reported psychosocial and physical functioning	Patients with higher perceived physical abilities were likely to survive more.
Butow et al. [74]	1999	Metastatic melanoma	Cognitive appraisal of threat+ coping + psychological adjustment + perceived aim of treatment + social support + QOL	Perceived aim of treatment, minimization, anger and better QOL were independently predictive of longer survival.
Brown et al. [75]	2000	Early stage melanoma		Shorter survival duration was associated with a positive mood.
Meyers et al. [76]	2000	Brain (recurrent glioblastoma multiforme or anaplastic astrocytoma)	FACT-Br + ADL	Measures of QOL and ADL were not independently related to survival.
de Graeff et al. [77]	2001	Head and neck	EORTC QLQ-C30 + QLQ-H&N35 + CES-D	Cognitive functioning was prognostic factor of survival while physical functioning, mood and global QOL were not.
Jerkeman et al. [78]	2001	Lymphoma	EORTC QLQ-C30	Pretreatment global QOL was an independent prognostic marker of survival.
Roychowdury et al. [79]	2003	Locally advanced and metastatic bladder	EORTC QLQ-C30	Longer survival was associated with high physical functioning, low role functioning and no anorexia.
Chiarion-Sileni et al. [80]	2003	Advanced melanoma	RSCL	Baseline overall QOL and the physical symptom distress scores were significant independent prognostic factors for survival.
Fang et al [81].	2004	Advanced head and neck	EORTC QLQ-C30 + QLQ-H&N35	Baseline fatigue was predictive of survival while changes in QOL scores during treatment were not.
Collette et al. [82]	2004	Symptomatic metastatic hormone-resistant Prostate	EORTC QLQ-C30	Insomnia and appetite loss were significant independent predictors of survival.
Monk et al. [83]	2005	Advanced cervix	FACT-G + Cervix subscale + FACT/GOG-Ntx+ BPI	Baseline FACT-Cx (FACT-G + Cervix subscale) scores was associated with survival.
Brown et al. [84]	2006	Brain (high grade glioma)	LASA scales (to measure overall QOL)+ FACT-Br + Fatigue (SDS) + excessive daytime somnolence (ESS) + depression (POMS-SF)	Fatigue was significant independent predictor of survival.

Table 6 (continued): Studies on relationship between quality of life data and survival in patients with different cancers

Author(s)	Year	Cancer	HRQOL measure(s)	Results*
Yeo et al. [85]	2006	Unresectable hepatocellular	EORTC QLQ-C30	Appetite loss, physical and role functioning scores were significant predictor of survival.
Lis et al. [86]	2006	Pancreatic	Ferrans and Powers QLI	Health and physical subscale was marginally significant predictor of survival.
Dubois et al. [87]	2006	Refractory multiple myeloma	EORTC QLQ-C30 + QLQ-MY24 + FACIT-Fatigue + FACT/GOG-Ntx	Fatigue was significant predictor of survival.
Sullivan et al. [88]	2006	Metastatic hormon-refractory prostate	EORTC QLQ-C30 + FACT-P	Baseline QOL scores (global QOL, physical, role, and social functioning and pain, fatigue and appetite loss) were significant predictors of survival.
Mauer et al. [89]	2007	Brain (anaplastic oligodendroglioma)	EORTC QLQ-C30 + QLQ-BN20	Emotional functioning, communication deficit, future uncertainty, and weakness of legs were significant prognostic of survival. Baseline QOL scores added little to clinical factors to predict survival.
Mauer et al. [90]	2007	Brain (glioblastoma)	EORTC QLQ-C30 + QLQ-BN20	Cognitive functioning, global health status, and social functioning were significant prognostic factors of survival. Baseline QOL scores added little to clinical factors to predict survival.
Fielding and Wong [37]	2007	Liver and lung	FACT-G	Global QOL scores did not predict survival in liver cancer. Physical well-being predicted survival in lung cancer.
Lehto et al. [91]	2007	Localized melanoma	Coping with cancer + anger expression, perceived social support + life stresses + single item QOL	Anger non-expression, hopelessness, over-positive reporting of QOL reduced survival while denial/minimizing response to the diagnosis as such predicted longer survival.
Bonnetain et al. [92]	2008	Advanced hepatocellular carcinoma	Spitzer QLI	Baseline QOL was independent prognostic factor for survival.
Carey et al. [93]	2008	Advanced ovarian cancer	EORTC QLQ-C30	Performance status and global QOL scores at baseline were prognostic factors for both progression-free survival and overall survival.
Gupta et al. [94]	2008	Ovarian cancer	Ferrans and Powers QLI	No statistically significant prognostic association of patient satisfaction with QOL was observed with survival.

Abbreviations: ADL: Activities of Daily Living; BPI: Brief Pain Inventory; CES-D: Centre for Epidemiologic Studies-Depression Scale; EORTC QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire; ESS: Epworth Sleepiness Scale; FACIT-Fatigue: Functional Assessment of Chronic Illness Therapy-Fatigue scale; FACT-Br: Functional Assessment of Cancer Therapy-Brain module; FACT-G: Functional Assessment of Cancer Therapy-General module; FACT-P: Functional Assessment of Chronic Illness Therapy- prostate module; LASA: Linear Analog Self Assessment; POMS-SF: Profile of Mood State-Short Form; PROSQOL: Prostate Cancer-Specific Quality-of-Life Instrument; QLI: Quality of Life Index; QLQ-BN20: EORTC Brain Cancer specific Quality of Life Questionnaire; QLQ-H&N35: EORTC Head and Neck Cancer specific Quality of Life Questionnaire; FACT/GOG-Ntx: FACT Gynecologic Oncology Group Neurotoxicity scale; QLQ-MY24: EORTC Myeloma specific Quality of Life Questionnaire; QLQ-PR25: EORTC Prostate Cancer specific Quality of Life Questionnaire; QOL: quality of life; RSCL: Rotterdam Symptom Checklist; SDS: Symptom Distress Scale.

* All results obtained from multivariate analyses after controlling for one or more demographic and known biomedical prognostic factors.

Discussion

Although a helpful review on the topic was published recently [95], this is the first comprehensive study that reviewed the prognostic value of quality of life data for survival time in cancer patients. The review contained 88 studies and apart from a few

exceptions in most instances the results indicated that health-related quality of life data or some aspects of quality of life measures were significant predictors of survival duration.

Early studies reported here were used ad hoc instruments while recent studies used well-validated cancer-specific quality of life questionnaires. Even

most recent studies supplemented site-specific questioner in their assessments. The EORTC QLQ-C30 was found to be the most utilized cancer-specific instrument and as one could observe in tables provided in this review in many occasions the questionnaire showed relatively consistent and reliable results. The EORTC QLQ-C30 and its supplementary modules such as QLQ-BR23, QLQ-LC13 and QLQ-BN20 are very useful instruments to be applied in prognostic factors analyses providing that other methodological requisites are ensured.

Many reported that global or overall quality of life was found to be independent significant predictor of survival. Global quality of life is usually a very straightforward question that in general asks people to evaluate their own health status or quality of life individually or in combined. It is argued measures such as global quality of life are patient-rated and thus are have potentials to reflect patients' well-being better than physicians observed indicators. However, it has been recommended that for instance since global quality of life scale of the EORTC QLQ-C30 is highly correlated with other scales, it should not be included in prognostic factor analyses when using other variables from the EORTC QLQ-C30 in order to achieve model stability [96].

There were several measures such as physical functioning that particularly showed significant association with the length of survival in cancer patients. It is argued that physical functioning might be a surrogate marker of an unrecognized biological prognostic factor and thus one should not conclude a causative association between physical functioning and survival time [58].

Among symptoms, appetite loss, pain and fatigue were found to be most important or strongest independent predictors of survival in many different studies among different cancer populations. One possible explanation is that these symptoms are very sensitive markers of the patients' well-beings. In addition as explained by Efficace et al. [51], such findings might be due to the fact that in multivariate analyses other quality of life measures mask each other in effect and therefore variables such as appetite loss or pain or fatigue appear as most important or strongest predictors of the length of survival.

As suggested by Gotay et al. [95] there are several explanations for association between health-related quality of life data and survival duration in cancer outcome studies. They summarized four possible explanations: (i) quality of life measures include different items and thus provide more sensitive information than traditional performance

status and toxicity measures; (ii) quality of life data, especially those collected at baseline before disease progression, could pick up relevant information earlier that established clinical prognostic factors; (iii) quality of life data are markers of patients' behavior as it relates to the disease diagnosis, its treatment and subsequent outcomes; and that (iv) quality of life data are markers of individual characteristics such as personality style, and adapting coping strategies that affect the process and outcomes in cancer patients.

This review intended to include studies that examined the relationship between quality of life data and survival and thus excluding pure psychological studies that report on association between psychological data and survival. However, inevitably some papers that in principle belonged to psychological discipline were included in this review. Usually these papers reported that they incorporated a measure of quality of life in their studies, although for assessing the quality of life did not use well-known instruments. Contradictory to expectation, these papers found that in multivariate analyses better conditions such as over-positive reporting of quality of life [91] or having a better appetite were indicators of shorter survival [47].

This review was based on a single data bank that is MEDLIN and manual search only. In addition the search strategy was based on keywords in titles of the English language publications. Thus there is a risk for missing other possible papers, although manual search might be reduced the risk. Furthermore, the review was not examined the individual reports in details and thus the findings are not inclusive. However, as Bottomley and Efficace in their editorial stated studies on relationships between quality of life data and survival duration achieved considerable evidence, although it is still a relatively novel area of research in oncology and long way to go remain. As suggested more prospective studies that are hypothesis driven are needed to provide robust evidence to show that health-related quality of life data and patient-reported outcomes independently predict length of survival [97].

In conclusion, studies reported in this review provide evidence for a positive relationship between quality of life data or some aspects of quality of life measures and the length of survival in cancer patients. Pre-treatment quality of life data are appeared to be most reliable information that could help clinicians to establish prognostic criteria for treatment of their cancer patients. Indeed, conducting studies using valid instruments, applying sound methodological approaches and adequate but not

sophisticated multivariate statistical analyses adjusted for demographic characteristics and known clinical prognostic factors are recommended in order to yield more specific quality of life related prognostic variables for specific cancers.

Acknowledgment

The author wishes to thanks Mrs. T. Rostami for her secretarial assistance. This was a piece of pure academic research work and the author did not receive any financial support or grant for the study.

References

1. Montazeri A, Gillis CR, McEwen J. Measuring quality of life in oncology: is it worthwhile? Part I. Meaning, purposes, and controversies. *Eur J Cancer Care*.1996; 5: 159-167.
2. Montazeri A, Gillis CR, McEwen J. Measuring quality of life in oncology: is it worthwhile? Part II. Experiences from the treatment of cancer. *Eur J Cancer Care*. 1996; 5: 168-175.
3. Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR. How quality of life data contribute to our understanding of cancer patients' experiences? A study of patients with lung cancer. *Qual Life Res*.2003; 12: 157-166.
4. Montazeri A, McEwen J, Gillis CR. Quality of life in patients with ovarian cancer: the current state of the research. *Support Care Cancer*.1996; 4: 169-179.
5. Montazeri A, Gillis CR, McEwen J. Quality of life in patients with lung cancer: a review of literature from 1970 to 1995. *Chest*.1998; 113: 467-481.
6. Montazeri A. Health-related quality of life in breast cancer patients: a bibliographic of the literature from 1974 to 2007. *J Exp Clin Cancer res* .2008; 27: 32.
7. Pater JL, Loeb M. Nonanatomic prognostic factors in carcinoma of the lung: a multivariate analysis. *Cancer*.1982; 50: 326-331.
8. Cassileth BR, Lusk EJ, Miller DS, Brown LL, Miller C. Psychosocial correlates of survival in advanced malignant disease? *N Engl J Med*.1985; 312: 1551-555.
9. Coates A, Gebiski V, Bishop JF, Jeal PN, Woods RL, Snyder R, Tattersall MH, et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategy. *N Engl J Med*.1987; 317: 1490-1495.
10. Kaasa S, Mastekaasa A, Lund E. Prognostic factors for patients with inoperable non-small cell lung cancer, limited disease. The importance of patients' subjective experience of disease and psychosocial well-being. *Radiother Oncol*.1989; 15: 235-242.
11. Degner LF, Sloan JA. Symptom distress in newly diagnosed ambulatory cancer patients and as a predictor of survival in lung cancer. *J Pain Symptom Manage*.1995; 10: 423-431.
12. Ringdal GI, Götestam KG, Kaasa S, Kvinnsland S, Ringdal K. Prognostic factors and survival in a heterogeneous sample of cancer patients. *Br J Cancer*.1996; 73: 1594-1599.
13. Tamburini M, Brunelli C, Rosso S, Ventafridda V. Prognostic value of quality of life scores in terminal cancer patients. *J Pain Symptom Manage* .1996; 11: 32-341.
14. Coates A, Porzsolt F, Osoba D. Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. *Eur J Cancer* .1997; 33: 1025-1030.
15. Danczy J, Zee B, Osoba D, Whitehead M, Lu F, Kaizer L, Latreille J, et al. Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. *Qual Life Res*.1997; 6: 151-158.
16. Chang VT, Thaler HT, Polyak TA, Kornblith AB, Lepore JM, Portenoy RK. Quality of life and survival: the role of multidimensional symptom assessment. *Cancer*.1998 83: 173-179.
17. Ganz PA, Lee JJ, Siu J. Quality of life assessment. An independent prognostic variable for survival in lung cancer. *Cancer*.1991; 67: 3131-3135.
18. Ruckdeschel JC, Piantadosi S. Quality of life in lung cancer surgical adjuvant trial. *Chest*.1994; 106: 324-328.
19. Loprinzi CL, Laurie JA, Wieand HS, Krook JE, Novotny PJ, Kugler JW, Bartel J, et al. Prospective evaluation of prognostic variables from patient-completed questionnaires. North Central Cancer Treatment Group. *J Clin Oncol*.1994; 12: 601-607.
20. Buccheri GF, Ferrigno D, Tamburini M, Brunelli C. The patient's perception of his own quality of life might have an adjunctive prognostic significance in lung cancer. *Lung Cancer*.1995; 12: 45-58.
21. Buccheri G. Depressive reactions to lung cancer are common and often followed by a poor outcome. *Eur Respir J*.1998; 11: 173-178.
22. Herndon JE 2nd, Fleishman S, Kornblith AB, Kosty M, Green MR, Holland J. Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma? *Cancer*.1999; 85: 333-340.
23. Langendijk H, Aaronson NK, de Jong JM, ten Velde GP, Muller MJ, Wouters M. The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy. *Radiother Oncol*. 2000; 55: 19-25.
24. Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR. Quality of life in lung cancer patients: as an important prognostic factor. *Lung Cancer*.2001; 31: 233-240.
25. Auchter RM, Scholtens D, Adak S, Wanger H, Cella DF, Mehta MP. Quality of life assessment in advanced non-small-cell lung cancer patients undergoing an accelerated radiotherapy regimen: report of ECOG study 4593. *Int J Radiat Oncol Biol Phys*.2001; 50: 1199-1206.
26. Moinpour CM, Lyons B, Grevstad PK, Lovato LC, Growley J, Czaplicki K, Buckner ZM, et al. Quality of life in advanced non-small-cl lung cancer: results of a Southwest Oncology Group randomized trial. *Qual Life Res*.2002; 11: 115-126.
27. Nakahara Y, Mochizuki Y, Miyamoto Y, Tanaka A, Kawamura T, Sasaki S, Nakahara Y, Katsura Y. Mental state as a possible independent prognostic variable for

survival in patients with advanced lung carcinoma. *Cancer*.2002; 94: 3006-3015.

28. Naughton MJ, Herndon JE, Shumaker SA, Miller AA, Kornblith AB, Chao D, Hollan J. The health – related quality of life and survival of small-cell lung cancer patients: Results of a companion study to CALGB 9033. *Qual Life Res*.2002; 11: 235-248.

29. Etom DT, Fairclough DJ, Cella D, Yount SE, Bonomi P, Johnson DH. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from eastern cooperative oncology group study 5592. *J Clin Oncol*.2003; 21: 1536-1543.

30. Dharma-Wardene M, Au HJ, Hanson J, Dupere D, Hewitt J, Feeny D. Baseline FACT-G score is a predictor of survival for advanced lung cancer. *Qual Life Res*. 2004; 13: 1209-1216.

31. Nowak AK, Stockler MR, Byrne MJ. Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity, and results of using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module. *J Clin Oncol*.2004; 22: 3172-3180.

32. Maione P, Perrone F, Gallo C, et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. *J Clin Oncol*.2005; 23: 6865-6872.

33. Brown J, Thorpe H, Napp V, Fairlamb DJ, Gower NH, Milroy R, Parmar MK, et al. Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer. *J Clin Oncol*.2005; 23: 7417-727.

34. Efficace F, Bottomley A, Smit EF, Lianes P, Legrand C, Debruyne C, Schramel F, et al. the EORTC Lung Cancer Group and Quality of Life Unit. Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. *Ann Oncol*.2006; 17: 1698-1704.

35. Sundström S, Bremnes RM, Brunsvig P, Aasebø U, Kaasa S. Norwegian Lung Cancer Study Group. Palliative thoracic radiotherapy in locally advanced non-small cell lung cancer: can quality-of-life assessments help in selection of patients for short- or long-course radiotherapy? *J Thorac Oncol*.2006; 1: 816-824.

36. Bottomley A, Coens C, Efficace F, Gaafar R, Manegold C, Burgers S, Vincent M, et al. EORTC-NCIC. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. *J Clin Oncol*.2007; 25: 5770-5776.

37. Fielding R, Wong WS. Quality of life as a predictor of cancer survival among Chinese liver and lung cancer patients. *Eur J Cancer*.2007; 43: 1723-1730.

38. Jacot W, Colinet B, Bertrand D, Lacombe S, Bozonnat MC, Daurès JP, Pujol JL. OncoLR health network. Quality of life and comorbidity score as prognostic determinants in

non-small-cell lung cancer patients. *Ann Oncol* 2008; 19: 1458-1464.

39. Coates A, Gebiski V, Signorini D, Murray P, McNeil D, Byrne M, Forbes JF. Prognostic value of quality of life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trial Group. *J Clin Oncol*.1992; 10: 1833-1838.

40. Fraser SC, Ramirez AJ, Ebbes SR, Fallowfield LJ, Dobbs HJ, Richards MA, Bates T, et al. A daily diary for quality of life measurement in advanced breast cancer trials. *Br J Cancer*.1993; 67: 341-346.

41. Seidman AD, Portenoy R, Yao TJ, Lepore J, Mont EK, Kortmansky J, Onetto N, et al: Quality of life in phase II trials-A study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel, plus granulocyte colony stimulating factor. *J Natl Cancer Inst*.1995; 187: 1316-1322.

42. Tross S, Herndon J, Korzun A, Kornblith AB, Cella DF, Herndon JF, Raich P, et al. From the Cancer and Leukemia Group B. psychosocial symptom and disease – free and overall survival in women with stage II breast cancer. *J Natl Cancer Inst*.1996; 88: 661-667.

43. Watson M, Haviland JS, Greer S, Davidson J, Bliss JM. Influence of psychological response on survival in breast cancer: a population-based cohort study. *Lancet*.1999 16: 1331-1336.

44. Coates AS, Hurny C, Peterson HF, Bernhard J, Castiglione-Gertsch M, Gelberg D, Goldhirsch A: Quality of life scores predict outcome in metastatic but not early breast cancer. International Breast Cancer Study Group. *J Clin Oncol*.2000, 18: 3768-3774.

45. Kramer JA, Curran D, Piccart M, de Haes JC, Bruning PF, Klijn JG, van Hoorebeek I, et al. Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. *Eur J Cancer*.2000, 36: 1498-1506.

46. Shimozuma K, Sonoo H, Ichihara K, Tanaka K: The prognostic value of quality of life scores: preliminary results of an analysis of patients with breast cancer. *Surg Today*.2000; 30: 255-261.

47. Butow PN, Coates AS, Dunn SM. Psychosocial predictors of survival: Metastatic breast cancer. *Ann Oncol*.2000; 11: 469-474.

48. Luoma ML, Hakamies-Blomqvist L, Sjostrom J, Pluzanska A, Ottoson S, Mouridsen H, Bengtsson NO, et al. Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer. *Eur J Cancer*.2003, 39: 1370-1376.

49. Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN, Michaelson RA, et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. *J Clin Oncol*.2004; 22: 2061-2068.

50. Efficace F, Therasse P, Piccart MJ, Coens C, van Steen K, Welnicka-Jaskiewicz M, Cufer T, et al. Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: an international multicenter study. *J Clin Oncol*.2004; 22: 3381-3388.

51. Efficace F, Biganzoli L, Piccart M, Coens C, van Steen K, Cufer T, Coleman RE, et al. Baseline health-related quality of life data as prognostic factors in a phase III multicenter study of women with metastatic breast cancer. *Eur J Cancer*.2004; 40: 1021-1030.
52. Goodwin PJ, Ennis M, Bordeleau LJ, Pritchard KT, Trudeau Me, Koo J, Hood N. Health-related quality of life and psychosocial status in breast cancer prognosis: analysis of multiple variables. *J Clin Oncol*.2004; 22: 4184-4192.
53. Watson M, Homewood J, Haviland J, Bliss J. Influence of psychosocial response on breast cancer survival: 10-year follow-up of a population-based cohort. *European Journal of Cancer*.2005, 41: 1710-1714.
54. Lehto US, Ojanen M, Dyba T, Aromaa A, Kellokumpu Lehtinen P. Baseline psychosocial predictors of survival in localized breast cancer. *Br J Cancer*.2006; 94: 1245-1252.
55. Gupta D, Granick J, Grutsch JF, Lis CG. The prognostic association of health-related quality of life scores with survival in breast cancer. *Support Care Cancer*.2007; 15: 387-393.
56. Groenvold M, Petersen MA, Idler E, Bjorner JB, Fayers PM, Mouridsen HT. Psychosocial distress and fatigue predicted recurrence and survival in primary breast cancer patients. *Br J Cancer*.2007; 105: 209-219.
57. Blazeby JM, Brookes ST, Alderson D. Prognostic value of quality of life scores in patients with oesophageal cancer. *Br J Surg*.2000; 87:362-373.
58. Blazeby JM, Brookes ST, Alderson D. The prognostic value of quality of life scores during treatment for oesophageal cancer. *Gut*.2001; 49: 227-230.
59. Fang FM, Tsai WL, Chiu HC, Kuo WR, Hsiung CY. Quality of life as a survival predictor for esophageal squamous cell carcinoma treated with radiotherapy. *Int J Radiat Oncol Biol Phys* 2004; 58: 1394-1404.
60. Chau I, Norman AR, Cunningham D, Waters JS, Oates J. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer: pooled analysis from three multicenter, randomized, controlled trials using individual patient data. *J Clin Oncol*.2004; 23:295-2403.
61. Park SH, Cho MS, Kim YS, Hong J, Nam E, Park J, Cho EK, et al . Self-reported health-related quality of life predicts survival for patients with advanced gastric cancer treated with first-line chemotherapy. *Qual Life Res*.2008; 17: 207-214.
62. Bergquist H, Johnsson A, Hammerlid E, Wenger U, Lundell L, Ruth M. Factors predicting survival in patients with advanced oesophageal cancer: a prospective multicentre evaluation. *Aliment Pharmacol Ther*.2008; 27: 385-395.
63. McKernan M, Mcmillan Dc, Anderson JR, Angerson WJ, Stuart RC. The relationship between quality of life (EORT QLQ-C30) and survival in patients with gastro-oesophageal cancer. *J Clin Oncol*.2008; 98: 888-893.
64. Earlam S, Glover C, Fordy C, Burke D, Allen-Mersh TG. Relation between tumor size, quality of life, and survival in patients with colorectal liver metastases. *J Clin Oncol*.1996; 14: 171-175.
65. Maisey NR, Norman A, Watson M, Allen MJ, Hill ME, Cunningham D. Baseline quality of life predicts survival in patients with advanced colorectal cancer. *Eur J Cancer*.2002; 38: 1351-1357.
66. Lis CG, Gupta D, Granick J, Grutsch JF. Can patient satisfaction with quality of life predict survival in advanced colorectal cancer? *Support Care Cancer*.2006; 14: 1104-1110.
67. Efficace F, Bottomley A, Coens C, Van Steen K, Conroy T, Schöffski P, Schmoll H, et al. Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer? *Eur J Cancer*.2006; 42: 42-49.
68. Efficace F, Innominato PF, Bjarnason G, Coens C, Humblet Y, Tumolo S, Genet D. Chronotherapy Group of the European Organisation for Research and Treatment of Cancer. Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer. *J Clin Oncol*.2008; 26: 2020-2026.
69. Cassileth BR, Walsh WP, Lusk EJ. Psychosocial correlates of cancer survival: a subsequent report 3 to 8 years after cancer diagnosis. *J Clin Oncol*.1988; 6: 1753-1759.
70. Coates A, Thomson D, McLeod GR, Hersey P, Gill PG, Olver IN, Kefford R, et al. Prognostic value of quality of life scores in a trial of Chemotherapy with or without interferon in patients with metastatic malignant melanoma. *Eur J Cancer*.1993; 29: 1731-1734.
71. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. *J Clin Oncol*.1996; 14: 1753-1755.
72. Wistøff F, Hjorth M. Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. *Nordic Myeloma Study Group. Br J Haematol*.1997; 97: 29-37.
73. De Boer MF, Van den Borne B, Pruyn JF, Ryckman RM, Volovics L, Knecht PP, Meeuwis CA, et al. Psychosocial and physical correlates of survival and recurrence in patients with head and neck carcinoma: results of a 6-year longitudinal study. *Cancer*.1998; 83:2567-2579.
74. Butow PN, Coates AS, Dunn SM. Psychosocial predictors of survival in metastatic melanoma. *J Clin Oncol*.1999; 17: 2256.
75. Brown JE, Butow PN, Culjak G, Coates AS, Dunn SM. psychosocial predictors of outcome: time to relapse and survival in patients with early stage melanoma. *Br J Cancer*.2000; 83: 1448-1453.
76. Meyers CA, Hess KR, Yung WK, Levin VA. Cognitive function as predictor of survival in patients with recurrent malignant glioma. *J Clin Oncol*.2000; 18: 646-650.
77. de Graeff A, de Leeuw JR, Row WJ, Hordijk GJ, Blijham GH, Winnubst JA. Sociodemographic factors and quality of life as prognostic indicators in head and neck cancer. *Eur J Cancer*.2001; 37: 332-339.
78. Jerkeman M, Kaasa S, Hjermstad M, Kvaløy S, Cavallin-Stahl E. Health-related quality of life and its

potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial. *Med Oncol.*2001;18: 85-94.

79. Roychowdhury DF, Hayden A, Liepa AM. Health-related quality-of-life parameters as independent prognostic factors in advanced or metastatic bladder cancer. *J Clin Oncol.*2003; 21: 673-678.

80. Chiarion-Sileni V, Del Bianco P, De Salvo GL, Lo Re G, Romanini A, Labianca R, Nortilli R, et al. Italian Melanoma Intergroup (IMI). Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients. *Eur J Cancer.*2003; 39:1577-1585.

81. Fang FM, Liu YT, Tang Y, Wang CJ, Ko SF. Quality of life as a survival predictor for patients with advanced head and neck carcinoma treated with radiotherapy. *Cancer.*2004; 100: 425-432.

82. Collette L, Andel GA, Bottomley A, Oosterhof G, Albrecht W, Rrijke TM. Is baseline quality of life useful for predicting survival with hormone-Refractory prostate cancer? A pooled Analysis of three studies of the European organization for research and treatment of cancer genitourinary Group. *J Clin Oncol.*2004; 22: 3877-3885.

83. Monk BJ, Huang HQ, Cella D, Long HJ, Gynecologic oncology Group study. Quality of life outcome from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a gynecologic oncology group study. *J Clin Oncol.*2005; 23: 4617-4625.

84. Brown PD, Ballman KV, Rummans TA, Maurer MJ, Sloan JA, Boeve BF, Gupta L, et al. Prospective study of quality of life adults with newly diagnosed high-grade gliomas. *J Neurooncol.*2006; 76: 283-291.

85. Yeo W, Mo FK, Koh J, Chan AT, Leung T, Hui P, Chan L, et al. Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. *Ann Oncol.*2006; 17: 1083-1089.

86. Lis CG, Gupta D, Grutsch JF. Patient satisfaction with quality of life as a predictor of survival in pancreatic cancer. *Int J Gastrointest Cancer.*2006; 37: 35-44.

87. Dubois D, Dhawan R, Van de velde H, Esseltine D, Gupta S, Viala M, Loge C. Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma. *J Clin Oncol.*2006; 24: 976-982.

88. Sullivan PW, Nelson JB, Mulani PM, Sleep D. Quality of life as potential predictor morbidity and mortality in patients with metastatic hormone-refractory prostate cancer. *Qual Life Res.*2006; 15: 1297-1306.

89. Mauer ME, Taphoorn MJ, Bottomley A, Coens C, Efficace F, Sanson M, Brandes AA, et al. EORTC Brain Cancer Group. Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study. *J Clin Oncol.*2007; 25: 5731-5737.

90. Mauer M, Stupp R, Taphoorn MJ, Coens C, Osoba D, Marosi C, Wong R, et al. The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study. *Br J Cancer.*2007; 97: 302-307.

91. Lehto US, Ojanen M, Dyba T, Aromaa A, Kellokumpu Lehtinen P. Baseline psychosocial predictors of survival in localized melanoma. *J Psychosom Res.*2007; 63: 9-15.

92. Bonnetain F, Paoletti X, Collette S, Doffoel M, Bouché O, Raoul JL, Rougier P, et al. Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials. *Qual Life Res.*2008; 17: 831-843.

93. Carey MS, Bacon M, Tu D, Butler L, Bezjak A, Stuart GC. The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer. *Gynecol Oncol.*2008; 108: 100-105.

94. Gupta D, Grutsch JF, Lis CG. Patient satisfaction with quality of life as a prognostic indicator in ovarian cancer patients treated in an integrative treatment setting. *J Soc Integr Oncol.*2008; 6: 98-104.

95. Gotay CC, Kawamoto CT, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. *J Clin Oncol.*2008; 26: 1355-1363.

96. Van Steen K, Curran D, Kramer J, Molenberghs G, Van Verckem A, Bottomley A, Sylvester R. Multicollinearity in prognostic factor analyses using the EORTC QLQ-C30: identification and impact on model selection. *Stat Med.*2002; 21: 3865-3884.

97. Bottomley A, Efficace F. Predicting survival in advanced cancer patients: is it possible with patient-reported health status data? *Ann Oncol.*2006; 17: 1037-1038.